Amish Chaturvedi is an experienced market access professional with 26 years of experience in the Pharmaceutical industry including in Pricing, Market access, Reimbursement and Policy across EU and JAPAC region. At EVERSANA, he leads Pricing and Market Access practice for the APAC region. As a practice lead, Amish leverages his vast experience to support pharmaceutical, medical devices and biotech companies build Value and Access strategy for Asia-Pacific region including for key markets like Japan, China, India, South Korea, Taiwan and Australia. Amish has extensive experience in developing and optimizing value communication in the local context to improve relevance and impact on payers. In addition, Amish supports clients optimize their access and reimbursement strategies at a regional level and guides the development of HTA submissions at country level.   Prior to joining EVERSANA, Amish spent 15 years in Policy and Market Access functions as therapy area lead for Abbvie and Janssen in above country and affiliate level roles.  Amish has hands-on experience managing reimbursement submissions to multiple HTA agencies. He has a deep understanding of access policies in key European and Asia-Pacific markets and HTA requirements across JAPAC,EU4 and the UK. He has worked across multiple therapy areas including Oncology, Immunology, Neuroscience, Infectious Diseases and Vaccines. Amish holds a B-Pharm degree, MBA degree (Australian National University) and Health Economics degree from London School of Economics (LSE).

Sharon brings over 20 years of experience in assessing, developing, and delivering HTA reimbursement strategies for new pharmaceutical and biotech products. With a background in hospital pharmacy and roles in clinical research, in-licensing, strategic planning, health economics, and outcomes research at the Australian affiliates of Janssen, Roche, and AstraZeneca, Sharon possesses a deep understanding of the drug development process and a broad knowledge across various products and therapy areas. Since 2018, Sharon has been working independently providing a range of services to clients including local affiliates, academic units, not-for-profits, industry associations, and other consultancies. Through an ongoing collaboration with FingerPost, a UK-based firm specialising in market access and pricing strategy, Sharon contributes to global projects and conducts primary market research within Australia and Japan.

Anne-Maree is passionate about the potential of innovative technologies to improve health outcomes. An engineer by trade, she also has a masters in public policy, and combines a thorough knowledge of product development with a strong understanding of the broader health and innovation policy landscape. She started her career at the medical device innovator Cochlear, has been the Operations Manager at health IT startup Humanetix, and also spent several years as Policy Manager at pharmaceutical company MSD. She is currently Head of Strategic Policy Implementation at Medicines Australia.

Graduated from UWA with a Master of Science in Clinical Biochemist and worked in pathology labs for 15 years. Moved to sales, marketing and executive management roles, mostly in large IVD technology companies. Has lived and worked in the USA, China and almost all Asian and sub-continental countries. Dean has an extensive knowledge of the pathology testing and technology sector. He supported the early days of Australia’s Bowel Cancer Screening program roll out. Currently heading up Pathology Technology Australia - the peak body representing companies that develop, manufacture and supply the technology and consumables so vital to testing in human health.